Hoppa till innehållet
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED KINGDOM, THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, HONG KONG, NEW ZEALAND, SINGAPORE, SWITZERLAND, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
The rights issue of shares and warrants of series TO3 in Biosergen AB ("Biosergen" or the "Company"), which was announced on January 30, 2024 and approved by the extraordinary general meeting on March 1, 2024 (the "Rights Issue"), has been registered with the Swedish Companies Registration Office. Trading with paid subscribed units ("BTU") will thus cease and BTU will be replaced with shares and warrants of series TO3. The last day of trading with BTU is April 18, 2024. The warrants of series TO3 will be admitted to trading on Nasdaq First North Growth Market starting April 24, 2024, under the ticker "BIOSGN TO3" with ISIN-code SE0021628591. The outcome of the Rights Issue was announced on March 26, 2024.
The Rights Issue has been registered with the Swedish Companies Registration Office. The last day of trading with BTU is April 18, 2024. The record date for the conversion is April 22, 2024, after which the BTU will be converted into shares and warrants of series TO3.
Warrants of series TO3 subscribed for in the Rights Issue are expected to be available on the subscribers' depository/securities account on April 24, 2024. The first day of trading for warrants of series TO3 is Wednesday, April 24, 2024.
Warrants of series TO3
One (1) warrant of series TO3 entitles the holder to subscribe for one (1) new share in the Company at a subscription price corresponding to seventy (70) per cent of the volume weighted average share price during a period of ten (10) trading days between November 4, 2024 and November 15, 2024, but not less than SEK 0.30 and not more than SEK 0.50 per share. The warrants may be exercised for the subscription of shares during a period as from and including November 18, 2024 up to and including November 29, 2024.
Advisors
Mangold Fondkommission AB is the financial advisor to Biosergen in connection with the Rights Issue. Advokatfirman Hammarskiöld & Co AB is the legal advisor to the Company in connection with the Rights Issue.